The Chinese hamster ovary (CHO) cell line is not the future for biomanufacturing says Biogen, which will publish results from a study of alternative hosts later this year.
Dutch contract manufacturer PharmaCell B.V has signed a three-year Manufacturing Services Agreement to make cancer cell therapies for Lion Biotechnologies.
United BioPharma Inc. (UBP), with government backing, has selected GE Healthcare’s FlexFactory manufacturing platform for its new facility in Hsinchu Industrial Park, Taiwan.
Mab-Venture Biopharma has entered a collaboration to establish an antibody development and production plant in China incorporating Thermo Fisher’s single-use bioreactors and SmartFactory automated technology.
Sanofi Pasteur says heavy investment in messenger RNA (mRNA) is warranted as such technology could revolutionise vaccine development and manufacturing.
The US FDA has warned Lonza about operations at its facility in Walkersville, Maryland, raising concerns about validation and aseptic process simulations.
Hands-on teaching offers drugmakers, vendors and regulators a better understanding of bioprocessing, according to the managing director of a training facility in Leiden, The Netherlands.
Danaher reported mid-single-digit growth from its bioprocessing subsidiary Pall Life Science and expects a continued trajectory to support Biopharma’s filtration needs.
Samsung Bioepis’ Renflexis has become the second biosimilar of rheumatoid arthritis biologic Remicade (infliximab) to be recommended for approval in the US.
BioInvent International AB has acquired a range of different single-use bioreactors from Germany’s Merck to up monoclonal antibody (mAb) capacity at its plant in Lund, Sweden.
Tory Prime Minister Teresa May’s decision to call a snap general election to stymie political opposition of her stewardship of the UK’s withdrawal from the European Union will see the MHRA limit communication to essential information.
Sartorius Stedim Biotech (SSB) has announced a €23m ($24.6m) research and development (R & D) programme with funding from local government bodies La Region Provence-Alpes-Cote d’Azur and la Metropole Aix-Marseille Provence, France.
European biotech companies Valneva and Bavarian Nordic have entered a commercial agreement to develop cell-based vaccines using production methods that are faster and cheaper than methods that use hen’s eggs.
Price hikes and lack of innovation, or better buying power and end-to-end services? Experts are split on supplier M&A and its effect on biomanufacturers.
Scottish synthetic biology firm Synpromics has received £5.2M ($6.6M) to enhance its synthetic promoter design technology used in gene therapy development.
Manufacturing tweaks have severe effects on the quality and yield of stem cells, says Pluristem which has successfully scaled-up production through a decade of process development evolution.
Deutsche Post DHL Group’s contract logistics business, DHL Supply Chain, has announced its intention to acquire Brazilian transport service provider Polar Transportes.
MilliporeSigma has launched a range of high area cartridges and single use capsules it says gives biomanufacturers greater efficiency in the filtration step.
Smithfield Foods Inc. has tasked a new bioscience unit with turning byproducts from its pork business into supplies for regenerative meds and drug firms.
GE Healthcare has acquired cryopreservation technology firm Asymptote and says more investments are likely as it builds an “end-to-end ecosystem” for cellular therapy production services.
There is a growing trend among vendors to integrate automation technologies into their offerings says a bioprocessing expert, as GE Healthcare invests in its partner Zenith.
Abeona Therapeutics says it plans to file its single injection adeno-associated virus (AAV) gene therapy for Sanfilippo syndrome in the US in late 2018.
American-made biosimilars hold no advantage in the US market according to patient and physician groups which place emphasis on trusted and reputable manufacturers instead.
GE Healthcare has agreed to help Cellular Biomedicine Group (CBMG) develop CAR-T and stem cell production technologies to support its aim of making 10,000 cancer cell therapies a year.
Sumitomo Dainippon Pharma Co Ltd has ordered cell culture technologies from Hitachi as part of its effort to develop a treatment for Parkinson’s disease.
Medcision has started pushing its cell therapy thawing technology through an early adopter scheme designed to encourage adoption by firms with candidates in trials.
The only practical way to scale-up volumes of mesenchymal stem cells (MSCs) is by using microcarriers in single-use bioreactors, say scientists from A*STAR and Instituto Superior Técnico.
Morphotek Inc has launched an antibody-drug conjugate (ADC) services business incorporating its RESPECT site-specific conjugation technology and eribulin-linker toxin platform.
Xenetic Biosciences says success for Shire’s haemophilia A candidate SHP656 will validate its PolyXen drug delivery technology platform and could net the firm up to $100m.
Dispatches from the 1st Stem Cell Community Day, Hamburg
Process automation should be incorporated early when developing large scale cell therapy manufacturing platforms, according to a lead scientist from the UK Catapult.
Novartis and Kite Pharma have both submitted autologous leukemia candidates for review, paving the road for the first available chimeric antigen receptor (CAR) T cell therapy.
